{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:00:13Z","timestamp":1785304813292,"version":"3.55.0"},"reference-count":38,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH\u20101123701C"],"award-info":[{"award-number":["TCVGH\u20101123701C"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cyclin\u2010dependent kinase (CDK) 4\/6 inhibitors are standard for treating hormone receptor\u2010positive metastatic breast cancer when combined with endocrine therapy. However, comparisons of first\u2010line treatments are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>In this retrospective study, we aimed to determine the effects and safety of ribociclib and palbociclib as first\u2010line treatments for metastatic hormone receptor\u2010positive breast cancer in real\u2010world settings at two tertiary medical centers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>\n                      This retrospective observational study, conducted in two tertiary medical centers, included patients receiving palbociclib or ribociclib in combination with endocrine therapy. Treatment responses were assessed by imaging studies according to RECIST 1.1 criteria. The primary endpoint was 24\u2010month progression\u2010free survival (PFS). Safety outcomes were also recorded and compared between the treatment groups. The median follow\u2010up times for the ribociclib and palbociclib groups were 19.7 and 24.6\u2009months, respectively. The 24\u2010month PFS rates were comparable between the ribociclib and palbociclib cohorts (55.4% vs. 55.2%, respectively; hazard ratio [HR]\u2009=\u20091.110, 95% confidence interval [CI]: 0.605\u20132.035;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.736), but the objective response rate was significantly higher in the palbociclib group than in the ribociclib group (43.2% vs. 30.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.035). A high rate of dose reduction was observed in both cohorts due to treatment\u2010related toxicities (41.2% in the palbociclib group vs. 47.2% in the ribociclib group). The adverse effect profiles were comparable, although the incidence of grade 1 fatigue was slightly higher in the ribociclib group than in the palbociclib group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.043).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In Taiwanese real\u2010world practice, ribociclib and palbociclib demonstrated comparable 24\u2010month efficacy. Our findings show that dose reductions do not compromise targeted treatment efficacy, supporting proactive toxicity\u2010guided dose to optimize patient tolerability without sacrificing oncological outcomes in Asian populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cnr2.70630","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:06:01Z","timestamp":1784808361000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ribociclib and Palbociclib Are Safe and Effective for Treating Metastatic Breast Cancer: A Retrospective Study"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1801-4964","authenticated-orcid":false,"given":"Cheng\u2010Wei","family":"Chou","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Oncology Taichung Veterans General Hospital  Taichung Taiwan"},{"name":"Department of Post\u2010Baccalaureate Medicine, College of Medicine National Chung Hsing University  Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi\u2010Hung","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Surgery Kaohsiung Veterans General Hospital  Kaohsiung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia\u2010I.","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Surgery Pingtung Veterans General Hospital  Pingtung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiann\u2010Yi","family":"Hsu","sequence":"additional","affiliation":[{"name":"Biostatistics Task Force, Department of Medical Research Taichung Veterans General Hospital  Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-9179","authenticated-orcid":false,"given":"Chih\u2010Chiang","family":"Hung","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, Department of Surgery Taichung Veterans General Hospital  Taichung Taiwan"},{"name":"Department of Applied Cosmetology, College of Human Science and Social Innovation Hung Kuang University  Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1502-0840","authenticated-orcid":false,"given":"Yen\u2010Dun","family":"Tzeng","sequence":"additional","affiliation":[{"name":"Department of Surgery Kaohsiung Veterans General Hospital  Kaohsiung Taiwan"},{"name":"School of Medicine, College of Medicine National Sun Yat\u2010sen University  Kaohsiung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia\u2010Hua","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, Department of Surgery Taichung Veterans General Hospital  Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224505"},{"key":"e_1_2_11_3_1","first-page":"101","article-title":"Incidence and Mortality of Female Breast Cancer in the Asia\u2010Pacific Region","volume":"11","author":"Youlden D. R.","year":"2014","journal-title":"Cancer Biology & Medicine"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21754"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.26"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114663"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3032"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0266-x"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34015"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0620"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04129-4"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-5054-x"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.012"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00479-x"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06334-0"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105570"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103833"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.18.00173"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00137"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2000"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231216095"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.18.00239"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1125"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1203684"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108488"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231163121"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz090"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20173-5"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4767"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.451"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2182051"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1159\/000527917"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-024-01458-1"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221139678"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70630","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.70630","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:14:34Z","timestamp":1785302074000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/cnr2.70630"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70630","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2025-11-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70630"}}